Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)
Taiwan · Delayed Price · Currency is TWD 114.50
-9.00 (-7.29%)
At close: Aug 18, 2026
TPEX:7871 Revenue
In the year 2025, Elixiron Immunotherapeutics (Cayman) Limited had annual revenue of 50.29M TWD with 6,162.39% growth. Elixiron Immunotherapeutics (Cayman) Limited had revenue of 50.06M in the half year ending December 31, 2025.
Revenue
50.29M
Revenue Growth
+6,162.39%
P/S Ratio
135.65
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 50.29M | 49.48M | 6,162.39% |
| Dec 31, 2024 | 803.00K | -24.89M | -96.88% |
| Dec 31, 2023 | 25.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.